Valuation: Assembly Biosciences, Inc.

Market Cap 509M 441M 411M 378M 714M 48.4B 722M 4.83B 1.9B 24.22B 1.91B 1.87B 80.2B P/E 2026 *
-24.4x
P/E 2027 * -9.22x
Enterprise Value 509M 441M 411M 378M 714M 48.4B 722M 4.83B 1.9B 24.22B 1.91B 1.87B 80.2B EV / Sales 2026 *
11.2x
EV / Sales 2027 * 15.8x
Free-Float
71.58%
Yield 2026 *
-
Yield 2027 * -
1 day+0.02%
1 week+5.50%
Current month+5.50%
1 month-8.32%
3 months-10.36%
6 months+4.33%
Current year-22.11%
1 week 24.66
Extreme 24.66
26.92
1 month 24.5
Extreme 24.5
29.94
Current year 21.8
Extreme 21.795
34.68
1 year 18.5
Extreme 18.5
39.7
3 years 7.69
Extreme 7.692003
39.7
5 years 7.69
Extreme 7.692003
47.28
10 years 7.69
Extreme 7.692003
808.32
Manager TitleAgeSince
Chief Executive Officer 50 31/12/2022
Director of Finance/CFO - 04/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 70 03/06/2026
Director/Board Member 61 13/12/2017
Director/Board Member 68 05/08/2019
Date Insider Type Main position Quantity % Market Cap.
04/06/26 Free

Director

8,000 0.0514%
29/03/26 Free

Chief Technology Officer

26,000 0.1671%
08/08/25 BuyCompany 4,591,840 72.2409%
Change 5-day change 1-year change 3-year change Capi.($)
+0.02%+5.50%+40.46%+102.52% 509M
+0.90%-2.33%+0.68%+14.52% 48B
+1.49%+8.26%+410.20%+560.81% 41.13B
+3.61%-4.33%+28.77%+8.00% 37.56B
+1.33%+0.05%+6.55%+74.57% 35.91B
+2.42%+7.27%+14.90%+44.79% 29.86B
+0.23%-2.64% - - 16.12B
+1.82%-0.22%+33.77%+124.13% 16.05B
+1.25%+1.52%+4.62%+18.66% 13.76B
+4.35%-8.36%-1.62%-35.09% 12.1B
Average +1.70%-1.59%+59.81%+101.44% 25.1B
Weighted average by Cap. +1.75%-1.28%+82.05%+127.53%

Financials

2026 *2027 *
Net sales 45.47M 39.38M 36.71M 33.76M 63.74M 4.32B 64.45M 431M 169M 2.16B 171M 167M 7.16B 32.25M 27.93M 26.04M 23.95M 45.21M 3.07B 45.71M 306M 120M 1.53B 121M 118M 5.08B
Net income -20.46M -17.72M -16.52M -15.2M -28.69M -1.95B -29.01M -194M -76.2M -974M -76.85M -75.16M -3.22B -56.38M -48.83M -45.52M -41.86M -79.03M -5.36B -79.92M -535M -210M -2.68B -212M -207M -8.88B
Net Debt - -
Logo Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Employees
73
Date Price Change Volume
05/08/26 US$26.49 +0.19% 74,541
04/08/26 US$26.44 +4.26% 90,955
03/08/26 US$25.36 +1.00% 193,303
31/07/26 US$25.11 -3.65% 101,354
30/07/26 US$26.06 +3.78% 55,726
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
26.44USD
Average target price
50.00USD
Spread / Average Target
+89.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ASMB Stock